Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P061 - Real Clinical Practice of Using Immunotherapy In NSCLC Patients With EGFR Mutation (ID 201)
00:00 - 00:00 | Author(s): L. Shen
Immunotherapy (PD-1/PD-L1 inhibitors) has been shown to be less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, little is known regarding its performance in real-world. The efficacy of immunotherapy might be different in patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Herein, we carried out a retrospective study to describe real clinical outcomes when using PD-1/PD-L1 inhibitors to treat NSCLC patients with EGFR mutation.
We retrospectively identified 27 patients with EGFR mutation-positive NSCLC who were treated with PD-1/PD-L1 inhibitors between January 2017 and April 2018.
Of 27 patients included in our study, 40.7% (n=11) harbored EGFR ex19del, 51.9% (n=14) harbored EGFR L858R, 3.7% (n=1) harbored EGFR G719X and 3.7 % (n=1) harbored EGFR ex20S768I. A total of 26 patients were treated with PD-1/PD-L1 inhibitors after disease progression during treatment with at least one EGFR-TKI and only one patient was EGFR-TKI na